top of page
Anti-Claudin 18.2 (clone QR120)

Anti-Claudin 18.2 (clone QR120)

Claudin 18.2 (CLDN18.2) – A Selective Biomarker and Therapeutic Target in Gastrointestinal Cancers
Overview of CLDN18.2
Claudin 18.2 (CLDN18.2) belongs to the claudin family, a group of membrane proteins forming tight junctions that regulate permeability, barrier function, and epithelial layer polarity.
CLDN18.2 is the dominant isoform in normal gastric tissue; however, its expression often persists and undergoes changes during malignant transformation. As a result, CLDN18.2 serves as a highly selective biomarker, frequently exhibiting aberrant expression during the development and progression of various malignancies, particularly:
✔ Gastric cancer (GC)
✔ Esophagogastric junction adenocarcinoma (EGJA)
Due to its tumor-specific expression, CLDN18.2 is being explored as a therapeutic target for GC/EGJA treatment.
Clinical Significance of CLDN18.2 in Gastric and Esophagogastric Junction Cancers
✔ Gastric cancer (GC) is the fifth most diagnosed malignancy and the third leading cause of cancer-related deaths worldwide.
✔ Esophagogastric junction adenocarcinoma (EGJA) is the ninth most common cancer and the sixth leading cause of cancer mortality globally.
✔ In the United States, only 6% of patients with metastatic GC/EGJA survive 5 years post-diagnosis.
✔ The majority of gastric cancers are diagnosed at an advanced or metastatic stage, where surgical intervention (combined with neoadjuvant and adjuvant therapy) is no longer an option.
The Role of CLDN18.2 in Cancer Diagnosis and Therapy
✔ Routine biomarker testing could significantly reduce diagnostic time and improve treatment selection.
✔ Immunohistochemical (IHC) CLDN18 testing is increasingly adopted in clinical practice to identify patients eligible for anti-CLDN18.2 therapy.
CLDN18.2 Expression in Metastases and Other Cancers
✔ CLDN18.2 can be expressed in metastatic gastric adenocarcinoma, including lymph node and distant site metastases.
✔ CLDN18.2 expression has also been observed in:
• Esophageal cancer
• Pancreatic cancer
• Mucinous ovarian carcinoma
• Non-small cell lung cancer (NSCLC)
Given its high specificity and selective expression, CLDN18.2 is emerging as a crucial diagnostic and therapeutic biomarker, particularly in gastrointestinal cancers.

    • [1] Angerilli V et al. (2024). Pathol Res Pract. 254:155145.

      [2] Pellino A et al. (2021). J Pers Med. 11(11):1095.

      [3] Tsukita S et al. (2019). Trends Biochem Sci. 44(2):141-52.

      [4] Hu YJ et al. (2013). Mol Biol Rep. 40(11):6123-42.

      [5] Sahin U et al. (2008). Clin Cancer Res. 14(23):7624-34.

    • ADVANTAGES OF RECOMBINANT RABBIT MONOCLONAL ANTIBODIES

      Recombinant rabbit monoclonal antibodies—referred to as Q-clones—combine the best properties of both murine monoclonal and rabbit polyclonal antibodies, offering a broader diagnostic potential.

      Key Advantages of Our Next-Generation Recombinant Rabbit Monoclonal Antibodies

      ✔ High Affinity due to rabbit origin, enabling greater sensitivity in assays—these antibodies bind strongly to antigens and maintain their bond even under challenging conditions, unlike low-affinity antibodies.

      ✔ Superior Specificity with reduced risk of cross-reactivity, thanks to their monoclonal nature.

      ✔ Expanded Antigen Recognition—better recognition of diverse antigens and epitopes.

      ✔ Target Epitopes Poorly Recognized by Mouse-Derived Antibodies, improving detection in certain applications.

      ✔ Enhanced Response to Small-Sized Epitopes, making them ideal for challenging targets.

      ✔ Significantly Improved Recognition of Murine Antigens, broadening their usability in research and diagnostics.

      ✔ Lower Background Staining, ensuring cleaner and more reliable results.

      Recombinant vs. Hybridoma Antibody Generation

      ✔ Exceptional Consistency, Specificity, and Sensitivity—eliminating risks of gene loss, mutations, or cell line drift.

      ✔ Reliable and Controlled Production—generated from a unique gene set, ensuring stable antibody performance.

      ✔ Batch-to-Batch Consistency, guaranteeing reproducible results and long-term product availability.

      ✔ Efficient In Vitro High-Throughput Production, allowing easy standardization and scalable antibody expression for any application.

      Recombinant rabbit monoclonal antibodies represent the future of immunohistochemistry, offering unmatched reliability and precision in diagnostic and research settings.

    bottom of page